Zacks Investment Research
14 Aug 2026, 16:36 UTC · 13h ago
PetMed Express Q1 Earnings Miss Estimates, Sales Decline Y/Y
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
14 Aug 2026, 16:36 UTC · 13h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
PetMed Express (PETS) reported first-quarter fiscal 2027 net sales of $41 million, a 19.9% decline year-over-year. — A significant double-digit drop in top-line revenue indicates weakening demand, specifically in prescription medication sales.
-0.60PetMed Express missed both top and bottom line Zacks Consensus Estimates for the first quarter. — Missing analyst expectations typically triggers negative short-term price action as the market recalibrates valuation.
-0.40The company's loss per share narrowed to 28 cents, compared to a $1.65 loss in the prior-year quarter. — While still loss-making, the reduction in loss shows an improvement in the bottom line, though largely due to the absence of one-time impairment charges.
+0.20Continue reading
6 related stories
Search tags
Recurring net sales as a percentage of total gross sales increased to 61.5% from 57.6%. — An increase in recurring revenue suggests improved customer retention and more predictable future cash flows.
+0.20Customer acquisition cost decreased by 15% year-over-year to $60 per customer. — Lower acquisition costs indicate improved marketing efficiency, though this is a secondary metric compared to the overall sales decline.
+0.10Which stocks this story touches
The company reported first-quarter results missing both top and bottom line estimates, with a significant year-over-year decline in net sales.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
6h ago
